In particular, LOXL2 modulates the invasive ability of breast cancer cells by regulating the activity of the extracellular proteins tissue inhibitor of metalloproteinases-1 (TIMP1) and MMP-9 56. This evidence concerns the gene TIMP1 and breast carcinoma.